

Medium term outcomes following primary focal therapy using HIFU for localised prostate cancer

L. Dickinson, H. Ahmed, N. McCartan, A. Freeman, A. Kirkham, C. Allen, R. Hindley, M. Emberton
Department of Urology, University College Hospitals, London NHS Foundation Trust, London, United Kingdom

Introduction: A limited number of prospective studies have evaluated the role of focal therapy for localised prostate cancer, demonstrating encouraging short-term cancer control with low rates of genito-urinary side-effects. We evaluated the medium term (>2 year) outcomes from trial patients followed-up within a prospective registry.

Methods: Of 118 men with localised prostate cancer (T1c-T3a, Gleason grade $\leq 4+3$, PSA <20) treated (Sonablate® 500 HIFU) in 3 Phase I/II prospective ethics-committee approved trials (hemi, focal, or index lesion ablation), 88 have completed at least 24 months follow-up. Cancer control was assessed using histological outcomes (post-HIFU biopsies of treated or suspicious areas) and biochemical disease-free survival (BDFS) using Stuttgart (PSA nadir + 1.2ng/ml) and Phoenix (PSA nadir + 2ng/ml) criteria. Composite disease free status was defined as histological absence of disease, or BDFS in the absence of post-operative biopsies. Functional outcomes were assessed using validated patient questionnaires (IPSS, IIEF-15, UCLA EPIC-Urinary).

Results: Median follow-up was 32 months (range 24–69). Mean number of focal treatments was 1.2. There was one non-prostate cancer related death. Absence of any cancer was 72% (52/72), and absence of clinically significant cancer (≤ 3 mm Gleason 3+3) was 86% (62/72) on post-operative biopsy. BDFS was 66% (57/87) and 82% (71/87) using Stuttgart and Phoenix criteria, respectively. Composite disease free status was 80% and 86%, using Stuttgart and Phoenix criteria, respectively. Four men (5%) required salvage radiotherapy or adjuvant hormones. Grade III rectal toxicity occurred in 1 man, with resolution on conservative management. Preservation of continence was 99% (86/87) pad-free, and 85% (56/66) leak-free pad-free. The rate of preserved erectile function was 89% (76/85), including 40% new PDE-5 inhibitor use (32/81).

Conclusions: Our results indicate that the short-term functional benefits of focal therapy seem to extend into medium term follow-up, alongside encouraging cancer control. Longer-term outcomes are still required.